Preclinical studies with erlotinib (Tarceva)
RW Akita, MX Sliwkowski - Seminars in oncology, 2003 - Elsevier
Erlotinib HCl (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
Erlotinib (Tarceva): an update on the clinical trial program
RS Herbst - Seminars in oncology, 2003 - Elsevier
Erlotinib HCI (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
quinazoline-based agent that competes with adenosine triphosphate for binding with the …
quinazoline-based agent that competes with adenosine triphosphate for binding with the …
Erlotinib (Tarceva®): a promising drug targeting epidermal growth factor receptor tyrosine kinase
AM Bulgaru, S Mani, S Goel… - Expert review of …, 2003 - Taylor & Francis
Overexpression of the epidermal growth factor receptor (EGFR) is correlated with a poor
prognosis in several human malignancies. In addition, cancers overexpressing EGFR …
prognosis in several human malignancies. In addition, cancers overexpressing EGFR …
Targeting HER1/EGFR in cancer therapy: experience with erlotinib
G Giaccone - Future Oncology, 2005 - Taylor & Francis
Research into the role of the human epidermal receptor growth factor receptor 1/epidermal
growth factor receptor (HER1/EGFR) in tumorigenesis has generated a new class of …
growth factor receptor (HER1/EGFR) in tumorigenesis has generated a new class of …
Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of Erlotinib (Tarceva)
M Hidalgo, D Bloedow - Seminars in oncology, 2003 - Elsevier
Pharmacokinetic and pharmacodynamic studies have an important role in the optimization
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl …
Erlotinib: preclinical investigations.
M Hidalgo - Oncology (Williston Park, NY), 2003 - europepmc.org
Erlotinib (Tarceva) is an orally available selective small-molecule inhibitor of HER1/EGFR
tyrosine kinase with a 50% inhibitory concentration of 2 nM for purified tyrosine kinase. This …
tyrosine kinase with a 50% inhibitory concentration of 2 nM for purified tyrosine kinase. This …
Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines
Q Dai, YH Ling, M Lia, YY Zou, G Kroog, KK Iwata… - Clinical Cancer …, 2005 - AACR
Abstract Purpose: Erlotinib (Tarceva, OSI-774) is a potent and specific inhibitor of the
HER1/epidermal growth factor receptor (EGFR) tyrosine kinase. In phase II clinical studies …
HER1/epidermal growth factor receptor (EGFR) tyrosine kinase. In phase II clinical studies …
Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.
A Sandler - Oncology (Williston Park, NY), 2003 - europepmc.org
In phase I trials in healthy volunteers and patients with refractory cancers, erlotinib (Tarceva)
was well tolerated and showed activity against non-small-cell lung cancer and other tumors …
was well tolerated and showed activity against non-small-cell lung cancer and other tumors …
A review of erlotinib and its clinical use
PA Tang, MS Tsao, MJ Moore - Expert opinion on pharmacotherapy, 2006 - Taylor & Francis
Erlotinib is an orally available, reversible tyrosine kinase inhibitor of the epidermal growth
factor receptor. Encouraging activity as a single agent and in combination with other …
factor receptor. Encouraging activity as a single agent and in combination with other …
A review of erlotinib–an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor
R Iyer, A Bharthuar - Expert opinion on pharmacotherapy, 2010 - Taylor & Francis
Importance of the field: The epidermal growth factor receptor (EGFR) is a cell surface
receptor for EGF and transforming growth factor-alpha which is overexpressed by a number …
receptor for EGF and transforming growth factor-alpha which is overexpressed by a number …